Cited by 83Thyroid Disorders and TreatmentsDrug Solubulity and Delivery SystemsPharmacogenetics and Drug Metabolism

Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide

Liel, Yair, Sperber, Ami D., Shany, Shraga·1994·The American Journal of Medicine

Abstract

Purpose To evaluate the adverse effect of aluminum hydroxide on levothyroxine pharmacokinetics in hypothyroid patients and study the mechanism of this effect.Design An in vivo open study supplemented by in vitro experiments.Setting A university hospital-based outpatient service.Intervention Administration for 2 to 4 weeks of an aluminum hydroxide-containing preparation to patients balanced on replacement thyroxine therapy.Measurements Serum thyrotropin (TSH).Results A significant increase in serum TSH was observed during seven periods of aluminum hydroxide administration (7.19 +/- 1.3 versus 2.62 +/- 0.8 mU/L; P = 0.012). In vitro studies indicated a considerable nonspecific adsorptive capacity of aluminum hydroxide for thyroxine.Conclusions The results indicate an adverse effect of aluminum hydroxide on levothyroxine bioavailability through a mechanism involving nonspecific adsorption, or complexing, of levothyroxine to aluminum hydroxide. We recommend close monitoring of serum TSH levels in patients receiving oral thyroid hormone replacement therapy who concurrently take aluminum hydroxide-containing medications. Adjustment of the levothyroxine dose, or cessation of the antacid, may be necessary.

Integrity signals

Registry

Crossref · 10.1016/0002-9343(94)90303-4

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only two of the medications that alter LT4 absorption have been studied in a cross-over study design of chronic therapy, with two other studies also conducted prospectively.

    “Only two of these medications have been studied in a cross-over study design of chronic therapy (132,145), with two other studies also conducted prospectively (140,143).”
  • Following documentation of increased LT4 requirement in a patient taking an aluminum-containing antacid (142), the same investigators showed an increase in TSH levels in five patients who were asked to take aluminum hydroxide with their LT4 (143).

    “Following documentation of increased LT4 requirement in a patient taking an aluminum-containing antacid (142), the same investigators showed an increase in TSH levels in five patients who were asked to take aluminum hydroxide with their LT4 (143).”
  • Direct complexation and chelation play important roles in the malabsorption of LT4 induced by the intake of many drugs, including calcium and iron supplements, aluminum-containing antacids, bile acid sequestrants, and some foods (eg, fiber-rich foods, coffee, and milk).

    “It is widely acknowledged that direct complexation and chelation play important roles in the malabsorption of LT4 induced by the intake of many drugs, including calcium and iron supplements (72, 73), aluminum-containing antacids (74), bile acid sequestrants (75, 76), and some foods (eg, fiber-rich foods, coffee, and milk) (22, 77, 78).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liel, Y., Sperber, A. D., & Shany, S.
Affiliations
Ben-Gurion University of the Negev (IL)
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1994-10
Volume
97
Issue
4
Pages
363-365
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2068307987
Cited by
83
References
13
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 1
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
levothyroxine, aluminum hydroxide, drug adsorption, drug interactions, hypothyroidism, thyroid hormone replacement, serum thyrotropin, antacids, bioavailability
MeSH terms
Adsorption, Aluminum Hydroxide, Ambulatory Care, Humans, Hypothyroidism, Intestinal Mucosa, Intestines, Thyrotropin, Thyroxine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review